Imatinib therapy prior to myeloablative allogeneic stem cell transplantation

[1]  J. Radich,et al.  A Retrospective Study of Patients Treated with Imatinib Mesylate Prior to Allogeneic Hematopoietic Stem Cell Transplant. , 2004 .

[2]  E. Kimby,et al.  Combination Therapy with Rituximab and Fludarabine in Waldenstrom’s Macroglobulinemia. , 2004 .

[3]  J. Radich,et al.  Allogeneic hematopoietic stem cell transplantation for chronic myeloid leukemia. , 2004, Hematology/oncology clinics of North America.

[4]  T. Lipp,et al.  Early prediction of response in patients with relapsed or refractory Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ALL) treated with imatinib. , 2004, Blood.

[5]  M. Freund,et al.  Treosulfan and fludarabine: a new toxicity-reduced conditioning regimen for allogeneic hematopoietic stem cell transplantation. , 2004, Blood.

[6]  Yoo-Jin Kim,et al.  Minimal residual disease-based role of imatinib as a first-line interim therapy prior to allogeneic stem cell transplantation in Philadelphia chromosome-positive acute lymphoblastic leukemia. , 2003, Blood.

[7]  W. Knopińska-Posłuszny,et al.  Modification of the clonogenic capacity of bone marrow cells from normal individuals by the tyrosine kinase inhibitor STI571. , 2003, Clinical and laboratory haematology.

[8]  J. Eary,et al.  166Ho-DOTMP plus melphalan followed by peripheral blood stem cell transplantation in patients with multiple myeloma: results of two phase 1/2 trials. , 2003, Blood.

[9]  Susan Branford,et al.  Detection of BCR-ABL mutations in patients with CML treated with imatinib is virtually always accompanied by clinical resistance, and mutations in the ATP phosphate-binding loop (P-loop) are associated with a poor prognosis. , 2003, Blood.

[10]  M. Minden,et al.  Imatinib Mesylate (Gleevec™) is a Useful Agent in the Salvage Treatment of Adults with Relapsed/refractory Philadelphia Positive Acute Leukemias , 2003, Hematology.

[11]  S. Sohn,et al.  Cardiac morbidity in advanced chronic myelogenous leukaemia patients treated by successive allogeneic stem cell transplantation with busulphan/cyclophosphamide conditioning after imatinib mesylate administration , 2003, British journal of haematology.

[12]  J. Ford,et al.  Practical management of patients with chronic myeloid leukemia receiving imatinib. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  J. Ford,et al.  Imatinib treatment: specific issues related to safety, fertility, and pregnancy. , 2003, Seminars in hematology.

[14]  Francisco Cervantes,et al.  Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. , 2003, The New England journal of medicine.

[15]  C. Chuah,et al.  Imatinib mesylate (STI-571) given concurrently with nonmyeloablative stem cell transplantation did not compromise engraftment and resulted in cytogenetic remission in a patient with chronic myeloid leukemia in blast crisis , 2003, Bone Marrow Transplantation.

[16]  N. Kröger,et al.  Imatinib mesylate (STI571) in preparation for allogeneic hematopoietic stem cell transplantation and donor lymphocyte infusions in patients with Philadelphia-positive acute leukemias , 2003, Leukemia.

[17]  A. Gratwohl,et al.  Increasing use of reduced intensity conditioning transplants: report of the 2001 EBMT activity survey , 2002, Bone Marrow Transplantation.

[18]  H. Gschaidmeier,et al.  Therapy with imatinib mesylate (Glivec) preceding allogeneic stem cell transplantation (SCT) in relapsed or refractory Philadelphia-positive acute lymphoblastic leukemia (Ph+ALL) , 2002, Leukemia.

[19]  C. Miething,et al.  Effects of imatinib on bone marrow engraftment in syngeneic mice , 2002, Leukemia.

[20]  D. Marin,et al.  Factors affecting duration of survival after onset of blastic transformation of chronic myeloid leukemia. , 2002, Blood.

[21]  K. Antman,et al.  Imatinib mesylate--a new oral targeted therapy. , 2002, The New England journal of medicine.

[22]  Sigrid Stroobants,et al.  Safety and efficacy of imatinib (STI571) in metastatic gastrointestinal stromal tumours: a phase I study , 2001, The Lancet.

[23]  C. Sawyers,et al.  Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. , 2001, The New England journal of medicine.

[24]  S. Woolf,et al.  An evidence-based analysis of the effect of busulfan, hydroxyurea, interferon, and allogeneic bone marrow transplantation in treating the chronic phase of chronic myeloid leukemia: developed for the American Society of Hematology. , 1999, Blood.

[25]  J Hermans,et al.  Risk assessment for patients with chronic myeloid leukaemia before allogeneic blood or marrow transplantation , 1998, The Lancet.

[26]  H. Heimpel,et al.  Survival with bone marrow transplantation versus hydroxyurea or interferon for chronic myelogenous leukemia. The German CML Study Group. , 1998, Blood.

[27]  J. Melo,et al.  The tyrosine kinase inhibitor CGP57148B selectively inhibits the growth of BCR-ABL-positive cells. , 1997, Blood.

[28]  E D Thomas,et al.  1994 Consensus Conference on Acute GVHD Grading. , 1995, Bone marrow transplantation.

[29]  G. McDonald,et al.  Veno-occlusive Disease of the Liver and Multiorgan Failure after Bone Marrow Transplantation: A Cohort Study of 355 Patients , 1993, Annals of Internal Medicine.

[30]  J. Klein,et al.  Bone marrow transplantation for leukemia following a new busulfan and cyclophosphamide regimen , 1987 .

[31]  H. Deeg,et al.  Methotrexate and cyclosporine compared with cyclosporine alone for prophylaxis of acute graft versus host disease after marrow transplantation for leukemia. , 1986, The New England journal of medicine.

[32]  B. Druker,et al.  Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapy , 2002, Leukemia.

[33]  S. Gupta,et al.  Hepatocyte transplantation: emerging insights into mechanisms of liver repopulation and their relevance to potential therapies. , 1999, Journal of hepatology.

[34]  J. Klein,et al.  Bone marrow transplantation for leukemia following a new busulfan and cyclophosphamide regimen. , 1987, Blood.